Research Categories
- Anesthesia
- Arthroscopy
- Biologics/Biomaterials
- Cancer Devices
- Cardiovascular
- Cosmetic Devices
- Dental
- Diabetes
- Diagnostics
- Dialysis
- Drug Delivery
- Ear, Nose, Throat
- Endoscopy
- Gastrointestinal (GI)
- General Surgery
- Gynecology Devices
- Healthcare IT
- Hearing Devices
- Imaging
- Immunology
- Infusion Therapy
- Laparoscopy
- Minimally Invasive Surgery
- Neurology Devices
- Oncology
- Operating Room Equipment
- Ophthalmics Devices
- Orthopedics
- Patient Monitoring
- Peripheral Vascular
- Respiratory Devices
- Robotics & Navigation
- Sleep Apnea & Diagnostics
- Spine
- Stents
- Telehealth & Telemedicine
- Tissue Repair
- Urology
- Vascular Access
- Video Hi-Tech
- Women's Health
- Wound Care
Report Library
Showing 577–588 of 696 resultsSorted by latest
Ulcerative Colitis Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ulcerative colitis in Europe, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Immunology Drugs Market Overview | Europe | 2018-2024 | MedView
The Europe immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics.
more...Ulcerative Colitis Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ulcerative colitis across the globe (12 countries), including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Rheumatoid Arthritis Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis across the globe (12 countries), including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Psoriasis Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat psoriasis across the globe (12 countries), including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Crohn’s Disease Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat Crohn’s disease across the globe (12 countries), including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Ankylosing Spondylitis Drug Market Analysis | Global | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis across the globe (12 countries), including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Ulcerative Colitis Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ulcerative colitis outside the U.S. and Europe, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Rheumatoid Arthritis Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis outside the U.S. and Europe, including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Psoriasis Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat psoriasis outside the U.S. and Europe, including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Crohn’s Disease Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat Crohn’s disease outside the U.S. and Europe, including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Ankylosing Spondylitis Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis outside the U.S. and Europe, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...